AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19825060 — intervention group
Group type: COMPARATOR
Intervention: Esmarch manoeuvre
Number of subjects: 50
Study 19825060 — intervention group
Group type: COMPARATOR
Intervention: nasopharyngeal airway
Number of subjects: 50
Study 19825060 — intervention group
Group type: COMPARATOR
Intervention: oropharyngeal airway
Number of subjects: 50
Study 17785483 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurazone-impregnated urinary catheters
Number of subjects: 212
Study 17785483 — intervention group
Group type: COMPARATOR
Intervention: Standard silicone catheters
Number of subjects: 212
Study 15293865 — intervention group
Group type: EXPERIMENTAL
Intervention: AS 195 360mg once daily for 6 weeks
Number of subjects: 71
Study 15293865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 11253467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac pacing
Number of subjects: 56000
Study 11253467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56000
Study 9683395 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (30 mg/kg)
Number of subjects: 6
Study 9683395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (caffeine free diet Coca-Cola)
Number of subjects: 6
Study 7832179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use during methadone maintenance (35 mg)
Number of subjects: 125
Study 7832179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use during buprenorphine maintenance (2 mg)
Number of subjects: 125
Study 7832179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use during buprenorphine maintenance (6 mg)
Number of subjects: 125
Study 7832179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use during methadone maintenance (120 mg)
Number of subjects: 125
Study 7832179 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance (35 mg)
Number of subjects: 125
Study 7832179 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine maintenance (2 mg)
Number of subjects: 125
Study 7832179 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine maintenance (6 mg)
Number of subjects: 125
Study 7832179 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance (120 mg)
Number of subjects: 125
Study 2979249 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS) containing bicarbonate
Number of subjects: 40
Study 2979249 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) without bicarbonate (chloride ions instead)
Number of subjects: 40
Study 30637672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (alcohol prevention program)
Number of subjects: 12738
Study 30637672 — intervention group
Group type: COMPARATOR
Intervention: Control group (education as normal)
Number of subjects: 12738
Study 30637672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (adjusted for recanting)
Number of subjects: 12738
Study 30637672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (males vs females)
Number of subjects: 12738
Study 28004395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 43
Study 28004395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 28004395 — intervention group
Group type: EXPERIMENTAL
Intervention: CMD
Number of subjects: 43
Study 24962607 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (24 International Units, twice-daily for 6 weeks) combined with social cognition training (2 × 1 hour weekly sessions for 6 weeks)
Number of subjects: 52
Study 24962607 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray combined with social cognition training (2 × 1 hour weekly sessions for 6 weeks)
Number of subjects: 52
Study 24962607 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (24 International Units, twice-daily for 6 weeks)
Number of subjects: 52
Study 23486191 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 113
Study 21857390 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (0, 1, or 2 mg iron/kg/d) from 6 weeks to 6 months of age
Number of subjects: 285
Study 21857390 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (2 mg group)
Number of subjects: 285
Study 21857390 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) infants
Number of subjects: 285
Study 21857390 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 285
Study 18827732 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 microg dexamethasone drug delivery system via a 22-gauge applicator insertion (n = 20)
Number of subjects: 30
Study 18827732 — intervention group
Group type: COMPARATOR
Intervention: 700 microg dexamethasone drug delivery system via a pars plana incisional placement (n = 10)
Number of subjects: 30
Study 16679203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic splint rapid maxillary expander followed by fixed appliances
Number of subjects: 51
Study 16679203 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 51
Study 15570141 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 19
Study 12880497 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 335
Study 12880497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 11120722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen alone, oral or transdermal
Number of subjects: 0
Study 11120722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen with cyclical progestagen (norethisterone)
Number of subjects: 0
Study 11120722 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 0
Study 11120722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral route
Number of subjects: 0
Study 11120722 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant (oestrogen and testosterone)
Number of subjects: 0
Study 11120722 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9124831 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly azithromycin (10 mg/kg)
Number of subjects: 159
Study 9124831 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly azithromycin (5 mg/kg)
Number of subjects: 159
Study 9124831 — intervention group
Group type: COMPARATOR
Intervention: Once-daily amoxicillin (20 mg/kg)
Number of subjects: 159
Study 9124831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both azithromycin and amoxicillin groups
Number of subjects: 159
Study 1433775 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g/day arginine hydrochloride
Number of subjects: 30
Study 1433775 — intervention group
Group type: COMPARATOR
Intervention: Mixed amino acid solution (Travasol)
Number of subjects: 30
Study 4033356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 9
Study 4033356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31072222 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching Performance Scale for Stroke (RPSS–Close and Far targets)
Number of subjects: 141
Study 31072222 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk compensatory movements
Number of subjects: 141
Study 31072222 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall regression models
Number of subjects: 141
Study 30335708 — intervention group
Group type: EXPERIMENTAL
Intervention: Two levels of immersive virtual reality simulation (VRS)
Number of subjects: 197
Study 30335708 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 197
Study 27270597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 105
Study 24891007 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 8
Study 24891007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22883586 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 70
Study 22883586 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy
Number of subjects: 70
Study 20610202 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (4%) scrub followed by alcohol impregnated with iodine (1%) solution
Number of subjects: 120
Study 18343087 — intervention group
Group type: EXPERIMENTAL
Intervention: Test of Memory Malingering (TOMM)
Number of subjects: 108
Study 18343087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dot Counting Test
Number of subjects: 108
Study 18343087 — intervention group
Group type: COMPARATOR
Intervention: Analog students (control group)
Number of subjects: 108
Study 16166438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH)
Number of subjects: 2600
Study 16166438 — intervention group
Group type: EXPERIMENTAL
Intervention: Central laboratory immunohistochemistry (10H8‐IHC)
Number of subjects: 2600
Study 16166438 — intervention group
Group type: COMPARATOR
Intervention: Outside/local laboratory immunohistochemistry
Number of subjects: 2600
Study 16166438 — intervention group
Group type: COMPARATOR
Intervention: BCIRG central laboratory 10H8‐IHC
Number of subjects: 2600
Study 16166438 — intervention group
Group type: COMPARATOR
Intervention: Unspecified FISH assay methods at outside/local laboratories
Number of subjects: 2600
Study 12924672 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term individual psychotherapy
Number of subjects: 0
Study 12924672 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance rated from patient perspective
Number of subjects: 0
Study 12924672 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance rated from therapist perspective
Number of subjects: 0
Study 10515836 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microgram of gB antigen with MF59 at 0, 1, and 2 months
Number of subjects: 95
Study 10515836 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microgram of gB antigen with MF59 at 0, 1, and 2 months
Number of subjects: 95
Study 10515836 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microgram of gB antigen with MF59 at 0, 1, and 4 months
Number of subjects: 95
Study 10515836 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microgram of gB antigen with MF59 at 0, 1, and 4 months
Number of subjects: 95
Study 10515836 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microgram of gB antigen with MF59 at 0, 1, and 6 months
Number of subjects: 95
Study 10515836 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microgram of gB antigen with MF59 at 0, 1, and 6 months
Number of subjects: 95
Study 8822431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction with intrauterine insemination (IUI)
Number of subjects: 100
Study 8822431 — intervention group
Group type: COMPARATOR
Intervention: Ovulation induction with timed intercourse (TI)
Number of subjects: 100
Study 1793648 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to blow noses
Number of subjects: 84
Study 1793648 — intervention group
Group type: COMPARATOR
Intervention: No advice given
Number of subjects: 84
Study 1793648 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally good nose blowers
Number of subjects: 84
Study 1793648 — intervention group
Group type: COMPARATOR
Intervention: Not naturally good nose blowers
Number of subjects: 84
Study 1793648 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (ventilating tubes)
Number of subjects: 84
Study 6167831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum/Bleomycin
Number of subjects: 21
Study 6167831 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate/vindesine
Number of subjects: 21
Study 31345051 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Home‐bAsed Reablement Program (I‐HARP)
Number of subjects: 18
Study 31345051 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 31115032 — intervention group
Group type: EXPERIMENTAL
Intervention: Simendan
Number of subjects: 80
Study 31115032 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 28202051 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (476 exams in 12 centers)
Number of subjects: 476
Study 28202051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography (310 exams in 9 centers)
Number of subjects: 476
Study 28202051 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (85 exams in 3 centers)
Number of subjects: 476
Study 28202051 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (199 exams in 9 centers)
Number of subjects: 476
Study 26048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg (8 × 50 mg capsules) after a standard meal
Number of subjects: 32
Study 26048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg (8 × 50 mg capsules) after a high‐fat meal
Number of subjects: 32
Study 26048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg (8 × 50 mg capsules) in the fed state (standard meal)
Number of subjects: 32
Study 26048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg (8 × 50 mg capsules) in the fed state (high‐fat meal)
Number of subjects: 32
Study 23528399 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneopeloid therapy with irrigation of high mineralized natural water and application of sapropel mud
Number of subjects: 127
Study 23528399 — intervention group
Group type: COMPARATOR
Intervention: Conventional periodontal treatment
Number of subjects: 127
Study 21716273 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (various doses)
Number of subjects: 0
Study 21716273 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (various doses)
Number of subjects: 0
Study 19699916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 130
Study 19699916 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 130
Study 16752267 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strain Lactobacillus plantarum LB931
Number of subjects: 191
Study 16752267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 191
Study 15596605 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/d for 6 weeks, then 10 mg/d
Number of subjects: 153
Study 15596605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 11684621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-copay group
Number of subjects: 0
Study 11684621 — intervention group
Group type: EXPERIMENTAL
Intervention: High-copay group
Number of subjects: 0
Study 11684621 — intervention group
Group type: COMPARATOR
Intervention: No-copay group
Number of subjects: 0
Study 9729054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (topical corticosteroid)
Number of subjects: 10
Study 7982651 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus isosorbide‐5‐mononitrate
Number of subjects: 30
Study 7982651 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 30
Study 7982651 — intervention group
Group type: COMPARATOR
Intervention: Elective sclerotherapy
Number of subjects: 30
Study 2500248 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-cm2 nitroglycerin adhesive transdermal patch applied for a single 24-hour period (q24hr)
Number of subjects: 24
Study 2500248 — intervention group
Group type: COMPARATOR
Intervention: 2% nitroglycerin ointment applied over a 50-cm2 area every eight hours (q8hr)
Number of subjects: 24
Study 4400557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericyazine
Number of subjects: 15
Study 528095 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital tablets, USP, 100 mg (7 different brands)
Number of subjects: 5
Study 528095 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital tablets, USP, 100 mg (Preparations A and E)
Number of subjects: 5
Study 528095 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital tablets, USP, 100 mg
Number of subjects: 5
Study 31880365 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride
Number of subjects: 45
Study 31880365 — intervention group
Group type: COMPARATOR
Intervention: l-DOPA
Number of subjects: 45
Study 31790404 — intervention group
Group type: EXPERIMENTAL
Intervention: Permagarden intervention
Number of subjects: 884
Study 29606364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 4710
Study 29606364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 4710
Study 29606364 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 4710
Study 29606364 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-amodiaquine
Number of subjects: 4710
Study 26272736 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Test-Stimulus (STS) protocol
Number of subjects: 65
Study 26272736 — intervention group
Group type: COMPARATOR
Intervention: Bath-Thermode protocol
Number of subjects: 65
Study 26272736 — intervention group
Group type: COMPARATOR
Intervention: Two-Thermodes protocol
Number of subjects: 65
Study 26272736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand immersion conditioning pain
Number of subjects: 65
Study 26272736 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermode pain
Number of subjects: 65
Study 26272736 — intervention group
Group type: COMPARATOR
Intervention: Conditioned test-stimulus pain scores for Bath-Thermode
Number of subjects: 65
Study 26272736 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned test-stimulus pain scores for STS
Number of subjects: 65
Study 26272736 — intervention group
Group type: COMPARATOR
Intervention: Conditioned test-stimulus pain scores for Two-Thermodes
Number of subjects: 65
Study 23994951 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 750 mg ± miconazole
Number of subjects: 43
Study 23994951 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg ± miconazole
Number of subjects: 43
Study 22863663 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation
Number of subjects: 26
Study 22863663 — intervention group
Group type: COMPARATOR
Intervention: Standard of care rehabilitation
Number of subjects: 26
Study 19246922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin for 14 days
Number of subjects: 20
Study 19246922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drugs for 14 days)
Number of subjects: 20
Study 17209663 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic drugs (SSRIs, dexfenfluramine, 5‐HT2C receptor agonists)
Number of subjects: 0
Study 17209663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine, dexfenfluramine, fluoxetine, chlorophenylpiperazine (mCPP)
Number of subjects: 0
Study 17209663 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐hydroxytryptophan, mCPP
Number of subjects: 0
Study 17209663 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT2C receptor selective agonists (lorcaserin)
Number of subjects: 0
Study 17209663 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT6 receptor antagonists (PRX‐07034, BVT74316)
Number of subjects: 0
Study 15189585 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma disclosure intervention
Number of subjects: 50
Study 15189585 — intervention group
Group type: COMPARATOR
Intervention: Control group (writing about plans for the next day)
Number of subjects: 50
Study 10715302 — intervention group
Group type: EXPERIMENTAL
Intervention: ACVBP
Number of subjects: 673
Study 10715302 — intervention group
Group type: COMPARATOR
Intervention: m-BACOD
Number of subjects: 673
Study 8882994 — intervention group
Group type: EXPERIMENTAL
Intervention: Force Velocity Test (FVT)
Number of subjects: 28
Study 8882994 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometry (ALV)
Number of subjects: 28
Study 8882994 — intervention group
Group type: EXPERIMENTAL
Intervention: Water displacement (WLV)
Number of subjects: 28
Study 8882994 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body mass
Number of subjects: 28
Study 1303863 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Sodium Cromoglycate used twice daily
Number of subjects: 0
Study 1303863 — intervention group
Group type: COMPARATOR
Intervention: 2% Sodium Cromoglycate used four times daily
Number of subjects: 0
Study 3856458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg po)
Number of subjects: 15
Study 3856458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3856458 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating (after fenfluramine)
Number of subjects: 15
Study 31393981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 119
Study 31393981 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 119
Study 28660870 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR) combined with Ergonomic Verbal Advice (EVA)
Number of subjects: 19
Study 28660870 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic Verbal Advice (EVA) only
Number of subjects: 19
Study 25529830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 2747
Study 25529830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2747
Study 23884013 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted bicycle training for 24 weeks
Number of subjects: 30
Study 23884013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training for 24 weeks)
Number of subjects: 30
Study 21430410 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen 160 mg
Number of subjects: 330
Study 21430410 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoprofen 60 mg
Number of subjects: 330
Study 21430410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 19364290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 45
Study 19364290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17919250 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless procedure
Number of subjects: 12